Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Spirit Airlines Shuts Down Flights, Issues Refunds After Financial Collapse 
Samsung Appoints New TV Business Head Amid Rising Competition from Chinese Rivals 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
Meta Plans $13B AI Data Center Financing in Texas Amid Surging Big Tech Investment 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Berkshire Hathaway Meeting Sees Shift as Greg Abel Steps Into Leadership Spotlight 
Regis Resources and Vault Minerals to Merge in $10.7B Gold Deal 
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
Anthropic’s $1.5B AI Venture with Wall Street Firms Targets Private Equity Market 
GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours 
SAN DIEGO, May 02, 2018 -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and wet age-related macular degeneration, announced today that it will report its first quarter 2018 financial and operating results after the close of U.S. financial markets on Wednesday, May 9, 2018. In addition, management will host a conference call to provide an update on corporate activities and discuss the quarterly financial results.
| Conference call and webcast: | |
| Date: | May 9, 2018 |
| Time: | 4:30 pm Eastern Time (1:30 pm Pacific Time) |
| Dial-in: | (855) 779-9066 (Domestic) or (631) 485-4859 (International) |
| Passcode: | 3189378 |
| Via web: | www.traconpharma.com; “Events and Presentations” section within the “Investors” section |
A replay of the webcast will be available for 60 days on the website.
About TRACON
TRACON develops targeted therapies for cancer and ophthalmic diseases. The Company’s clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with Santen Pharmaceutical Company Ltd.; TRC102, a small molecule being developed for the treatment of lung cancer and glioblastoma; and TRC253, a small molecule being developed for the treatment of prostate cancer. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.
| Company Contact: Patricia Bitar Chief Financial Officer (858) 550-0780 ext. 223 [email protected] | Investor Contact: Andrew McDonald LifeSci Advisors LLC 646-597-6987 [email protected] | |
